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Abstract
Oculocutaneous albinism (OCA) is a group of inherited disorders of melanin biosynthesis
characterized by a generalized reduction in pigmentation of hair, skin and eyes. The prevalence of
all forms of albinism varies considerably worldwide and has been estimated at approximately 1/
17,000, suggesting that about 1 in 70 people carry a gene for OCA. The clinical spectrum of OCA
ranges, with OCA1A being the most severe type with a complete lack of melanin production
throughout life, while the milder forms OCA1B, OCA2, OCA3 and OCA4 show some pigment
accumulation over time. Clinical manifestations include various degrees of congenital nystagmus,
iris hypopigmentation and translucency, reduced pigmentation of the retinal pigment epithelium,
foveal hypoplasia, reduced visual acuity usually (20/60 to 20/400) and refractive errors, color vision
impairment and prominent photophobia. Misrouting of the optic nerves is a characteristic finding,
resulting in strabismus and reduced stereoscopic vision. The degree of skin and hair
hypopigmentation varies with the type of OCA. The incidence of skin cancer may be increased. All
four types of OCA are inherited as autosomal recessive disorders. At least four genes are
responsible for the different types of the disease (TYR, OCA2, TYRP1 and MATP). Diagnosis is based
on clinical findings of hypopigmentation of the skin and hair, in addition to the characteristic ocular
symptoms. Due to the clinical overlap between the OCA forms, molecular diagnosis is necessary
to establish the gene defect and OCA subtype. Molecular genetic testing of TYR and OCA2 is
available on a clinical basis, while, at present, analysis of TYRP1 and MATP is on research basis only.
Differential diagnosis includes ocular albinism, Hermansky-Pudlak syndrome, Chediak-Higashi
syndrome, Griscelli syndrome, and Waardenburg syndrome type II. Carrier detection and prenatal
diagnosis are possible when the disease causing mutations have been identified in the family. Glasses
(possibly bifocals) and dark glasses or photocromic lenses may offer sufficient help for reduced
visual activity and photophobia. Correction of strabismus and nystagmus is necessary and
sunscreens are recommended. Regular skin checks for early detection of skin cancer should be
offered. Persons with OCA have normal lifespan, development, intelligence and fertility.
Disease name
Oculocutaneous albinism
Definition
Oculocutaneous albinism (OCA) is a group of four auto-
somal recessive disorders caused by either a complete lack
or a reduction of melanin biosynthesis in the melanocytes
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resulting in hypopigmentation of the hair, skin and eyes.
Reduction of melanin in the eyes results in reduced visual
acuity caused by foveal hypoplasia and misrouting of the
optic nerve fibres. The clinical spectrum of OCA varies,
with OCA1A being the most severe type characterized by
a complete lack of melanin production throughout life,
while the milder forms OCA1B, OCA2, OCA3 and OCA4
show some pigment accumulation over time. The differ-
ent types of OCA are caused by mutations in different
genes but the clinical phenotype is not always distinguish-
able, making molecular diagnosis a useful tool and essen-
tial for genetic counseling.
Epidemiology
Albinism can affect people of all ethnic backgrounds and
has been extensively studied. Approximately one in
17,000 people have one of the types of albinism [1]. This
suggests that about 1 in 70 people carry a gene for OCA.
Prevalence of the different forms of albinism varies con-
siderably worldwide, partly explained by the different
founder mutations in different genes and the fact that it
can be difficult clinically to distinguish between the differ-
ent subtypes of albinism among the large normal spec-
trum of pigmentation. OCA2 is the most prevalent form
worldwide [2] (Table 1).
• OCA1 has a prevalence of approximately 1 per 40,000
[3] in most populations but is very uncommon among
African-Americans.
• In contrast, OCA2 is the most common type of albinism
in African Black OCA patients. The overall prevalence of
OCA2 is estimated to be 1:36,000 in the USA, but is about
1:10,000 among African Americans [4]. It affects 1 in
3,900 of the population in some parts of the southern part
of Africa [5].
• OCA3 or Rufous oculocutaneous albinism has been
reported to affect 1:8,500 individuals in Africa, whereas it
is very rare in Caucasians and Asiatic populations [6].
• Recently, mutations in a fourth gene were shown to be
the cause of albinism, OCA4, [7] and were reported to
explain the disease in approximately 5–8% of German
patients with albinism [8] but 18% of Japanese patients
[9].
Clinical description
All types of OCA and ocular albinism (OA) have similar
ocular findings, including various degrees of congenital
nystagmus, hypopigmentation of iris leading to iris trans-
lucency, reduced pigmentation of the retinal pigment epi-
thelium, foveal hypoplasia, reduced visual acuity usually
in the range 20/60 to 20/400 and refractive errors, and
sometimes a degree of color vision impairment [1,10]
(Figure 1). Photophobia may be prominent. Iris translu-
cency is demonstrable by slit lamp examination. A charac-
teristic finding is misrouting of the optic nerves,
consisting in an excessive crossing of the fibres in the optic
chiasma, which can result in strabismus and reduced ster-
eoscopic vision [11]. The abnormal crossing of fibres can
be demonstrated by monocular visual evoked potential
[12]. Absence of misrouting excludes the diagnosis of
albinism.
The degree of skin and hair hypopigmentation varies with
the type of albinism but is in general reduced [10] (Table
1).
• In OCA1A the hair, eyelashes and eyebrows are white,
and the skin is white and does not tan. Irises are light blue
to almost pink, and fully translucent (Figure 2). Pigment
does not develop and amelanotic nevi may be present.
The symptoms do not vary with age or race. Visual acuity
is 1/10 or less, and photophobia is intense.
• In OCA1B, the hair and skin may develop some pigment
with time (after 1 to 3 years), and blue irises may change
to green/brown. Temperature-sensitive variants manifest
as having depigmented body hairs, and pigmented hairs
on hands and feet due to lower temperatures. Visual acu-
Table 1: The four known types of OCA
Gene Gene product Chr. localization Size Disease name Prevalence
TYR Tyrosinase (TYR) 11q14.3 65 kb (529aa) OCA1  1:40,000
OCA1A
OCA1B (Yellow alb.)
OCA2
(p gene)
OCA2 15q11.2-q12 345 kb (838aa) OCA2 (Brown OCA in Africans) 1:36,000 (white Europeans) 
1:3,900–10.000 (Africans)
TYRP1 Tyrosinase-related 
protein 1 (TYRP1)
9p23 17 kb (536aa) OCA3 (Rufous OCA) Rare (white Europeans, Asians) 
1:8,500 (Africans)
MATP Membrane-associated 
transporter protein 
(MATP)
5p13.3 40 kb (530aa) OCA4 Rare (white Europeans) 1:85,000 
(Japanese)Orphanet Journal of Rare Diseases 2007, 2:43 http://www.OJRD.com/content/2/1/43
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ity is 2/10. This phenotype was previously known as yel-
low albinism.
• In OCA2, the amount of cutaneous pigment may vary,
and newborn nearly always have pigmented hair. Nevi
and ephelids are common. Iris color varies and the pink
eyes seen in OCA1A are usually absent. Visual acuity is
usually better than in OCA1, and can reach 3/10. In Afri-
cans, brown OCA is associated with light brown hair and
skin, and gray irises. Visual acuity may reach 3/10.
• OCA3 results in Rufous or red OCA in African individu-
als, who have red hair and reddish brown skin (xan-
thism). Visual anomalies are not always detectable,
maybe because the hypopigmentation is not sufficient to
alter the development.
• OCA4 cannot be distinguished from OCA2 on clinical
findings.
Etiology
OCA is a group of congenital heterogeneous disorders of
melanin biosynthesis in the melanocytes (Figure 3). At
least four genes are responsible for the different types of
OCA (OCA1-4) (Table 1). Most patients are compound
heterozygotes, i.e. harbouring two different mutations in
one of the genes.
• OCA1 (MIM 203100) is caused by mutations in the
tyrosinase gene (TYR, MIM 606933) on chromosome
11q14.3 [13]. The gene consists of 5 exons spanning
about 65 kb of genomic DNA and encoding a protein of
529 amino acids [14]. TYR (EC 1.14.18.1) is a copper-con-
taining enzyme catalysing the first two steps in the mela-
nin biosynthesis pathway, converting tyrosine to L-
dihydroxy-phenylalanine (DOPA) and subsequently to
DOPAquinone [15]. Mutations completely abolishing
tyrosinase activity result in OCA1A, while mutations ren-
dering some enzyme activity result in OCA1B allowing
some accumulation of melanin pigment over time.
Almost 200 mutations in TYR are known [16]. As with all
recessive disorders, the "mildest" mutation is determining
for the phenotype. It has been shown that mutations in
the mouse Tyr gene cause the Tyr protein to be retained in
the endoplasmic reticulum, with subsequently early deg-
radation [17] (Figure 3).
• Mutations in the OCA2 gene (formerly known as the P-
gene) (MIM 203200) cause the OCA2 phenotype (MIM
203200) [18]. The gene consists of 24 exons (23 coding),
spanning almost 345 kb of genomic DNA in the region
15q11.2-q12, and encoding a protein of 838 amino acids
[19]. The OCA2 protein is a 110 kDa integral melano-
somal protein with 12 predicted transmembrane domains
[18,20]. OCA2 protein is important for normal biogenesis
of melanosomes [21,22], and for normal processing and
transport of melanosomal proteins such as TYR and
TYRP1 [23-26] (Figure 3). TYR stably expressed in a
human cell line is retained in perinuclear compartments;
this mislocalization can be reverted if OCA2 is co-
expressed [27]. It seems that OCA2 exerts at least some of
its effects by maintaining an acidic pH in melanosomes
[27]. In the Human Gene Mutation Database (HGMD)
[16], 72 mutations in OCA2 are listed to cause OCA.
• OCA3 (MIM 203290) is caused by mutations in tyrosi-
nase-related protein 1 (TYRP1, MIM 115501, 9p23) [28].
TYRP1 spans almost 17 kb genomic DNA, and consists of
8 exons encoding a protein of 536 amino acids [29].
TYRP1 is an enzyme in the melanin biosynthesis pathway,
catalysing the oxidation of 5,6-dihydroxyindole-2-carbox-
ylic acid (DHICA) monomers into melanin (Figure 3).
Studies of mouse melanocytes showed that Tyrp1 func-
tions to stabilize Tyr, and that mutations in Tyrp1 cause a
Fundus picture of a patient with albinism (a) and fundus pic- ture of a normal eye (b) Figure 1
Fundus picture of a patient with albinism (a) and fundus pic-
ture of a normal eye (b).
Eyes from a patient with OCA1A Figure 2
Eyes from a patient with OCA1A. Note that the irises are almost pink, and fully translucent.Orphanet Journal of Rare Diseases 2007, 2:43 http://www.OJRD.com/content/2/1/43
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delayed maturation and an early degradation of Tyr [17]
(Figure 3). Until recently, OCA3 was only known in indi-
viduals of African descent, however currently mutations in
TYRP1 have been identified in both a large Pakistani fam-
ily [30] and in a Caucasian patient [6].
• Mutations in the membrane-associated transporter pro-
tein gene (MATP, also known as SLC45A2, MIM 606202)
cause OCA4 (MIM 606574) [7]. MATP consists of 7 exons
spanning approximately 40 kb of genomic DNA, mapping
to chromosomal position 5p13.3. The MATP protein of
530 amino acids contains 12 putative transmembrane
domains and shows sequence and structural similarity to
plant sucrose transporters; it is expressed in melanosomal
cell lines [31,32]. The function of MATP is still unknown,
but studies from Medaka fish show that the MATP protein
plays an important role in pigmentation and probably
functions as a membrane transporter in melanosomes
[31] (Figure 3). Mutations in MATP were found for the
first time in a Turkish OCA patient [7], and have since
been found in German, Japanese and Korean OCA
patients [8,9,33,34].
Diagnostic methods
The diagnosis of OCA is based on clinical findings of
hypopigmentation of the skin and hair, in addition to the
characteristic ocular symptoms (Figure 1). However, due
to the clinical overlap between the OCA subtypes, molec-
ular diagnosis is necessary in order to establish the gene
defect and thus the OCA subtype. Molecular genetic test-
Tyrosinase (TYR) and Tyrosinase-related protein 1 (TYRP1) processing and the melanin biosynthetic pathway in the melano- cyte and in the melanosome, respectively Figure 3
Tyrosinase (TYR) and Tyrosinase-related protein 1 (TYRP1) processing and the melanin biosynthetic pathway in the melano-
cyte and in the melanosome, respectively. A) Schematic representation of melanosome biogenesis in the melanocyte and traf-
ficking of TYR and TYRP1 from the endoplasmatic reticulum (ER) via Golgi apparatus to the developing melanosome. Places 
are indicated where the transport or sorting of TYR and TYRP1 from the synthesis in the ER to the melanosomes is abolished 
caused by mutations in the four genes found to be responsible for OCA (OCA1 to OCA4, respectively) (adapted from [49]). 
B) Illustration of the melanin (eumelanin/pheomelanin) biosynthesis pathway in the melanosome. DHI: 5,6-Dihydroxyindole, 
DHICA: 5,6-Dihydroxyindole-2-carboxylic acid, TYR: tyrosinase, TYRP1: Tyrosinase-related protein 1 (DHICA oxidase), DCT: 
Dopachrome tautomerase.Orphanet Journal of Rare Diseases 2007, 2:43 http://www.OJRD.com/content/2/1/43
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ing of TYR and OCA2 are available on a clinical basis,
while at present, analysis of TYRP1  and  MATP  is on
research basis only. Molecular genetic testing is based on
mutational analysis of the genes, by standard screening
methods such as denaturing high performance liquid
chromatography (DHPLC) or single stranded conforma-
tional polymorphism (SSCP), followed by DNA sequenc-
ing.
Mutational analysis of TYR is complicated by the presence
of a pseudogene harbouring sequences highly similar to
exon 4 and 5 of TYR. This can be overcome either by diges-
tion of pseudogene sequences with restriction enzymes
prior to PCR amplification or by use of specific primers
only amplifying TYR sequences [35].
Due to the presence of numerous polymorphisms, muta-
tional analysis of OCA2 is difficult and until a functional
assay is available, investigation of control chromosomes
in addition to in silico analyses of amino acid substitutions
are necessary in order to substantiate the probable delete-
rious effect of a (missense) mutation.
Genetic counseling and antenatal diagnosis
All four types of OCA are inherited as autosomal recessive
disorders. Thus, the parents of an affected child are obli-
gate carriers, the recurrence risk for another affected child
is 25%, and healthy sibs are at 67% risk of being carriers.
Offspring of an affected person are obligate carriers. Car-
riers are asymptomatic.
In most cases, there is no previous family history of albi-
nism but the condition does occur in individuals of two
generations of a family, so called pseudodominance, and
is due to an affected person having children with a person
who is a carrier.
In African populations, there is a high frequency of OCA2
mutant alleles, hence affected patients in several genera-
tions may be seen.
Carrier detection and prenatal diagnosis are possible
when the disease causing mutations have been identified
in the family. Both disease causing mutations in an
affected person have to be identified and established to be
on the paternal and maternal chromosome, respectively,
before prenatal diagnosis can be performed in pregnan-
cies at 25% risk for an affected child. The testing can be
done on DNA extracted from chorion villus sampling
(CVS) at 10–12 weeks gestation or on DNA extracted from
cultured amniocytes. Preimplantation diagnosis using
molecular genetic analysis is also possible in principle,
but to our knowledge, this has not been carried out.
Previously, prenatal diagnosis has been performed on
skin biopsies from the fetus [36,37]. Requests for prenatal
diagnosis for OCA are not common, and may reflect the
nature of the condition (not affecting intellectual func-
tions or general health). However, many centers including
ours would consider prenatal testing after careful genetic
counseling of the parents.
Management
Management of eye problems
Reduced visual acuity can be helped in various ways. Clin-
ics specialized in low vision will provide the expertise.
Glasses, possibly bifocals, may often be of sufficient help.
Photophobia can be helped with dark glasses or
photocromic lenses that darken with exposure to bright
light. Nystagmus may be helped with contact lenses or
surgery of the eye muscles. Certain positions of the head
may dampen nystagmus. For strabismus it may be neces-
sary to patch one eye in children to force the non-pre-
ferred eye to be used.
Children should be given special attention at school, for
instance with high contrast written material, large type
textbooks, various optic devices as enlargement machines
(closed circuit TV), and the use of computers.
Skin
Most people with severe forms of OCA do not tan and eas-
ily get sunburned. Those forms with a little pigment devel-
oping with age may not be very bothered by the sun.
Sunscreens are recommended with at least a sun protec-
tion factor of 15. Ultraviolet rays can penetrate light T-
shirts especially when wet. Now, T-shirts have been devel-
oped which protect against the sun even when wet. The
incidence of skin cancer is increased in patients with OCA
[3]. Since the prevalence of OCA2 is high in Africa, this
may pose a serious health problem.
Differential diagnosis
It has become evident that heterogeneity exists within
oculocutaneous albinism, and several disorders with char-
acteristic of OCA in addition to other symptoms have
been identified. On the contrary, in Ocular Albinism
(OA) the hypopigmentation is limited to the eyes result-
ing in irides that are blue to brown, nystagmus, strabis-
mus, foveal hypoplasia, abnormal crossing of the optic
fibres and reduced visual acuity [38]. The gene OA1 is
localized on the X chromosome and only fibersboys are
affected [39]. In young boys with light complexion, of e.g.
Scandinavian extraction, some difficulty in the differential
diagnosis of OCA versus OA is not uncommon.
Among disorders where albinism is part of a larger syn-
drome are Hermansky-Pudlak syndrome (HPS), Chediak-
Higashi syndrome (CHS), Griscelli Syndrome, andOrphanet Journal of Rare Diseases 2007, 2:43 http://www.OJRD.com/content/2/1/43
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Waardenburg Syndrome type II (WS2). All, except WS2,
are inherited as autosomal recessive traits and can be dis-
tinguished on the basis of clinical and biochemical crite-
ria. Several subtypes exist within the different diagnoses.
Further, an association of hypopigmentation in Prader
Willi syndrome and Angelman disease with a deletion on
15q11 has been found, presumable caused by mutations
in OCA2 [40].
• The Hermansky-Pudlak syndrome is characterized by
hypopigmentation and the accumulation of a material
called ceroid in tissues throughout the body [41]. Further,
patients exhibit severe immunologic deficiency with neu-
tropenia and lack of killer cells [42]. HPS is very rare,
except in Puerto Rico where it affects approximately 1 in
1,800 individuals [43]. The most important medical prob-
lems in HPS are related to interstitial lung fibrosis, granu-
lomatous colitis and mild bleeding problems due to a
deficiency of granules in the platelets [44].
• The Chediak-Higashi syndrome is a rare condition that
includes an increased susceptibility to bacterial infections,
hypopigmentation, prolonged bleeding time, easy bruisa-
bility, and peripheral neuropathy. The skin, hair, and eye
pigment is reduced or diluted in CHS [45,46].
• The Griscelli syndrome is a rare disorder with immune
impairment or neurological deficit and hypopigmenta-
tion of skin and hair, and the presence of large clumps of
pigment in hair shafts [47].
• A syndrome of sensory deafness and partial albinism is
referred to as the albinism-deafness syndrome or the
Waardenburg syndrome [48].
Prognosis
Lifespan in patients with OCA is not limited, and medical
problems are generally not increased compared to those
in the general population. As mentioned, skin cancers
may occur and regular skin checks should be offered.
Development and intelligence are normal. Persons with
OCA have normal fertility.
Unresolved questions
We and others have identified mutations in two alleles in
approximately 50% of the patients investigated with
genetic screening of the four known OCA genes (OCA1-4)
(unpublished results). Further, some individuals classi-
fied with OCA1 or OCA2 have only one mutation identi-
fied. This means that a fraction of patients with albinism
still need to be genetically solved. Therefore, more work is
needed to establish whether subtle genetic changes in
regions not traditionally covered by genetic screening, i.e.
introns or regulatory domains are the cause of the disease
in cases with only one mutation identified. Further, large
genomic deletions or single exon deletions not identified
by traditional screening methods may explain the disease
in a fraction of the patients. In addition, a percentage of
genetically unresolved cases might be explained by muta-
tions in not yet identified OCA genes. Finally, the biolog-
ical function of the gene products of the genes identified
as the cause of albinism is not clarified and further eluci-
dation of these mechanisms may give clues to further can-
didate genes where mutations are the cause of new
subtypes of OCA.
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